Claritev (NYSE:CTEV) Announces Earnings Results, Beats Estimates By $5.45 EPS

Claritev (NYSE:CTEV) announced its quarterly earnings data on Monday. The company reported $1.77 earnings per share for the quarter, beating analysts’ consensus estimates of ($3.68) by $5.45, FiscalAI reports. The business had revenue of $268.31 million during the quarter.

Here are the key takeaways from Claritev’s conference call:

• Third-quarter revenue rose 9.1% year over year to $268.3 million and Adjusted EBITDA increased 4.4% to $162 million, exceeding expectations. Claritev raised its 2026 revenue, Adjusted EBITDA, and free cash flow guidance.
• Bookings reached $27 million in Q3 and topped $100 million year to date; the company now expects $115 million–$125 million for 2026, up 70%–90% from 2025. More than half of year-to-date bookings came from outside its core payer market, supporting management’s diversification strategy.
• Claims Intelligence grew 17.1%, with NSA dispute initiations up 75% year over year; management expects NSA activity to remain a tailwind. The company also said it expects at least $1.1 billion in revenue in 2027, a year ahead of its prior target.
• Payment & Revenue Integrity remained below plan as clients shifted from legacy clinical negotiations, more than offsetting growth in newer offerings. Management expects the segment to return to growth in 2027, but noted that bookings typically take time to convert to revenue.
• Claritev reported a $25.8 million Q3 free cash flow outflow and ended the quarter with $10.1 million of unrestricted cash, $95 million drawn on its revolver, and net leverage of 7.7x. Management expects a strong Q4 cash-flow rebound and reaffirmed its commitment to deleveraging.

Claritev Trading Down 3.9%

Shares of CTEV stock traded down $1.12 on Wednesday, reaching $27.55. 72,475 shares of the stock were exchanged, compared to its average volume of 173,875. The business’s 50 day moving average price is $26.90 and its 200 day moving average price is $25.47. The company has a market capitalization of $466.97 million, a price-to-earnings ratio of -1.68 and a beta of 1.05. Claritev has a twelve month low of $11.50 and a twelve month high of $61.22.

Insiders Place Their Bets

In other Claritev news, major shareholder Ares Management Llc acquired 20,834 shares of the stock in a transaction dated Monday, October 26th. The stock was acquired at an average cost of $24.07 per share, with a total value of $501,474.38. Following the transaction, the insider owned 1,933,939 shares in the company, valued at $46,549,911.73. The trade was a 1.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Travis Dalton acquired 1,950 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was acquired at an average price of $38.48 per share, for a total transaction of $75,036.00. Following the acquisition, the chief executive officer owned 52,322 shares in the company, valued at approximately $2,013,350.56. The trade was a 3.87% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 77,284 shares of company stock valued at $1,927,655 and have sold 23,687 shares valued at $769,078. Corporate insiders own 7.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CTEV shares. Zacks Research upgraded Claritev from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Barclays restated an “overweight” rating and set a $40.00 price target (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Wells Fargo & Company increased their price target on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Claritev from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a research report on Monday, September 21st. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

About Claritev

Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.